IDEXX Laboratories, Inc. - Common Stock (IDXX)
Healthcare › In Vitro & In Vivo Diagnostic Substances
Price History
Feb 9, 2026 — May 9, 2026Investment Snapshot
- Trading 615% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 8/9 — financially strong with improving fundamentals
- Strong ROE of 70.0% with 25.0% net margin
- Revenue growing at 10% annually
IDEXX Laboratories, Inc. - Common Stock (IDXX) is a Healthcare company operating in In Vitro & In Vivo Diagnostic Substances, listed on the NASDAQ , with a market capitalisation of $44.2 billion . Key value metrics: P/E ratio 40.5, P/B ratio 28.39, Piotroski F-Score 8 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
IDEXX Laboratories, Inc. - Common Stock — Fundamental Analysis Summary
IDEXX Laboratories, Inc. - Common Stock (IDXX) is currently trading 615% above its Graham Number of $78.30, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 40.5x.
On financial health, IDXX shows a strong Piotroski F-Score of 8/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 70.0% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.19.
StockPik's composite Value Score for IDXX is 62/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
IDXX reports a high gross margin of 62.6% (sector average: 40.1%) and a strong operating margin of 32.3%.
IDXX shows revenue growing at 10% year-over-year, with earnings growing at 19%.